TPS

THERABOND 3D based on its patented and proprietary 3D spacer fabric and silver metallurgy technologies, is a next generation antimicrobial wound dressing product line that is targeted at the unmet needs of burn management, chronic wounds, and surgical wounds. THERABOND 3D offers fluid and exudate management capabilities, conformability/comfort, economic and other benefits, while also offering state of the art antimicrobial activity, that have not been available until now.

THERABOND 3D's product line includes contact dressings, island dressings, our innovative wraps, and specialty products.

Key Advantages

• Fourteen (14) day antimicrobial action against a broad spectrum of pathogens
• Early antimicrobial action equal to, or better than, any product on the market
• 3D technology which enables efficient transfer of even heavy exudate away from the wound to an inexpensive outer/secondary dressing
• Does not become saturated and have to be replaced, minimizing dressing changes
• Hydrates easily and stays hydrated
• Soft and conformable, even on joints
• Provides gentle compression
• Does not sting or stain on application
• Does not fall off wet areas

Based on a proprietary and patented autocatalytic/electroless manufacturing process, the silver is bonded to the entire surface and released as ionic silver at a controlled rate in therapeutic levels over a 14 day period rather than "dumping" them quickly, as is characteristic of some other products. This prevents the staining associated with other products that utilize silver. The struts within the fabric act as capillaries moving excess fluid and exudate away from the wound to the outer absorbent dressing.

The effectiveness of ionic silver as an antimicrobial is well established. Laboratory data submitted to the FDA by Choice Therapeutics confirmed that Therabond 3D kills a broad spectrum of pathogens over a 14 day period. This includes antibiotic-resistant pathogens such as MRSA (methicillin-resistant Staph aureus) and VRE (vancomycin-resistant Enterococci sp.

This is a large, established market; and, the Therabond 3D product line is ideal for moderate to heavily exudating wounds such as venous stasis ulcers and diabetic ulcers. Due to systemic issues unrelated to the dressing, many of these wounds require and extended period to heal or do not fully heal. The clinical objective is to create the best possible healing environment.

Therabond 3D provides superior conformability, the ability to transfer fluid and exudates away from the wound, a moist, optimal healing environment, and 14 day antimicrobial protection. Dressing changes, patient trauma, medication use, demands on clinician time, and costs are minimized with Therabond 3D, making it the product of choice for this class of chronic wounds.

Specifically, Therabond 3D is ideal for venous leg ulcers treated with compression therapy and for diabetic foot ulcers treated with total contact casting. Therabond 3D offers an excellent solution for patients with either of these conditions. The Therabond 3D benefits for both conditions are the same. First, its antimicrobial action defends against infection. Secondly, and this is a benefit unique to Therabond 3D, the 3D fabric actively transports fluids away from the wound and surrounding skin into the absorptive layers that is applied under the compression therapy or the contact cast, eliminating maceration.

Wounds being prepared for grafting, complex open wounds, open traumatic wounds tunneling and undermining and as well as the contact layer for negative pressure wound therapy have all benefited from Therabond 3D. Therabond 3D offers an excellent solution for these types of wounds. Therabond 3D antimicrobial defends against infection. Therabond 3D actively transports fluids away from the wound into an an absorptive secondary dressing which promotes the most healing environment required for development of granulation tissue.

Post-operatively, surgical sites are subject to potential, devastating, surgical site infections (SSIs) and delayed healing. SSIs have been occurring even in procedures where the highest standard of asepsis (prevention of contact with microorganisms) have occurred. According to the Centers for Disease Control (CDC), antibiotic-resistant pathogens such as MRSA (methicillin-resistant Staphylococcus aureus) and VRE (vancomyscin-resistant enterococcus) are becoming ever more serious and even lethal problems.

Historically, the rate of SSIs in "clean" surgical sites such as coronary artery bypass surgery, hip replacement surgery, knee replacement surgery, and Caesarian section has been 1% - 3%. According to the Institute for Healthcare Improvement (www.ihi.org), "Infection rates up to 11 percent are [now] reported for certain types of procedures." This can add high costs that the hospital may not be able to recover.

High volume, high cost, high risk procedures include reconstructive surgery, vascular surgery, cardiothoracic surgery, caesarean sections, and orthopedic implants.

Therabond 3D offers exceptional clinical benefits that are designed to make it the product of choice for these clinical challenges. When used as the primary dressing of the surgical incision wound, Therabond 3D's antimicrobial action kills pathogens present at the wound site and surrounding skin, as well as any pathogens that come in contact with the dressing surface. It eliminates bio-burden at the wound sit, prevent bacteria from penetrating through the dressing and contamination the incision wound, and promotes rapid healing.

The burn market is an established market that is constantly seeking new, innovative products that improve patient care.

Burn wounds are at high risk for infection. The outer layer(s) of the skin no longer provide(s) a barrier to pathogens. Further, the patient is likely to be immunocompromised due to the severity of the injury.

In the burn center, Therabond 3D is used on donor sites, partial thickness burns, full thickness burns, and over grafts. Donor sites, partial thickness burns, and full thickness burns are at high risk of infection and, generally, output large amounts of exudate, especially in the first 24-48 hours. Grafts are fragile and must be protected.

Patient trauma, medication use, demands on clinician time, and cost are minimized the longer a dressing can stay on the wound. Therabond 3D has a 14 day indication, seven days longer than Acticoat and Mepilex Ag, two of the three major competitors. The third main competitor, Aquacel Ag, has a 14 day indication; but, like Acticoat and Mepilex Ag, it absorbs fluids and exudates rather than transferring them to an inexpensive, outer, absorbent dressing. As a result, dressing changes, patient trauma, medication use, demands on clinician time, and costs are minimized with Therabond 3D.

When the burn is treated with an advanced and expensive biologic product, the money spent on these products is wasted if there is an infection; and, the patient's agonizing and expensive hospital stay is lengthened. For this and other reasons, the prevention of infection is critical.

Therabond 3D offers early and sustained antimicrobial action equal to, or better than, any product on the market, is more comfortable and conformable, and is highly cost-effective. At a recent southeastern regional burn conference, a presentation given by a leading burn center highlighted a first year savings of approximately $100,000 over their previously used antimicrobial dressing.

To book a case or for further information call us at 1(610) 346-1992.

Steve Corsello
President, ACTIVIZE